SV and Polaris Back Gerngross' New Antibody Play
This article was originally published in Start Up
Executive Summary
Adimab is the latest venture in the resurgent large-molecule platform space. The company is founded by yeast platform pioneers Tillman Gerngross (Glycofi, Dartmouth) and Dane Wittrup (BioDisplay, MIT). The company's Series A pulled in $6.2 million from lead backers SV Life Sciences and Polaris Venture Partners.